<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852604</url>
  </required_header>
  <id_info>
    <org_study_id>1894-005</org_study_id>
    <secondary_id>IDX-06A-005</secondary_id>
    <nct_id>NCT01852604</nct_id>
  </id_info>
  <brief_title>Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)</brief_title>
  <official_title>A Randomized Study to Evaluate the Safety and Efficacy of IDX719 in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Subjects With Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parts A and B of this study are designed to evaluate the safety, tolerability, efficacy and
      pharmacokinetic profiles of samatasvir and simeprevir when administered in combination with
      ribavirin (RBV) for 12 weeks in treatment-naïve, Genotype (GT) 1b, 4 and 6 hepatitic C virus
      (HCV)-infected participants.

      Part C of this study is designed to evaluate the safety, tolerability, efficacy and
      pharmacokinetic profiles of samatasvir, simeprevir, TMC647055 and ritonavir (RTV) when
      administered in combination with or without RBV for 12 weeks in treatment-naïve or
      interferon/RBV-treatment relapsed, GT 1a and 1b HCV-infected participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A of this study is randomized and double-blind. Parts B and C are randomized and
      open-label.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who experienced an adverse event (AE)</measure>
    <time_frame>Up to approximately 95 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experienced a serious adverse event (SAE)</measure>
    <time_frame>Up to approximately 95 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experienced a Grade 1-4 laboratory abnormality</measure>
    <time_frame>Up to 66 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experienced sustained virologic response 4 weeks after the end of treatment (SVR4)</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who experienced rapid virologic response (RVR)</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who experienced early virologic response (EVR)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who experienced sustained virologic response 8 weeks after the end of treatment (SVR8)</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who experienced sustained virologic response 12 weeks after the end of treatment (SVR12)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who experienced sustained virologic response 24 weeks after the end of treatment (SVR24)</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter:Area under the concentration-time curve from time zero to t</measure>
    <time_frame>Days 1, 4, 7, 10, 14, 21, 28, 42, 56 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Maximum observed drug concentration (Cmax)</measure>
    <time_frame>Days 1, 4, 7, 10, 14, 21, 28, 42, 56 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Trough drug concentration (Ctrough)</measure>
    <time_frame>Days 1, 4, 7, 10, 14, 21, 28, 42, 56 and 84</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Chronic Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Participants with genotype 1b or 4 received samatasvir 50 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Participants with genotype 1b or 4 received samatasvir 100 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Participants with genotype 1b or 4 received samatasvir 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B: Participants with genotype 1b or 4 received samatasvir 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B: Participants with genotype 1b or 4 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: GT 6 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B: Participants with Genotype 6 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Samatasvir</intervention_name>
    <description>Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.</description>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part B: GT 6 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV</arm_group_label>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <description>Simeprevir will be supplied as 75 and 150 mg oral capsules.</description>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part B: GT 6 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV</arm_group_label>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.</description>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part B: GT 6 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV</arm_group_label>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC647055</intervention_name>
    <description>TMC647055 will be supplied as 150 mg oral capsules.</description>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV</arm_group_label>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir (RTV)</intervention_name>
    <description>Ritonavir will be supplied as 80 mg/mL oral solution.</description>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV</arm_group_label>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegylated interferon (Peg-IFN)</intervention_name>
    <description>Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.</description>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part B: GT 6 - samatasvir 100/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV</arm_group_label>
    <arm_group_label>Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samatasvir matching placebo</intervention_name>
    <description>Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.</description>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV</arm_group_label>
    <arm_group_label>Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have Genotype 1a, 1b, 4 or 6 HCV infection.

          -  Documented clinical history compatible with chronic hepatitis C

          -  HCV treatment-naïve or interferon/RBV-treatment relapsed (Part C)

          -  Must agree to use an acceptable double method of birth control (one of which must be a
             barrier method) for at least 6 months after the last dose of study drugs.

        Exclusion Criteria:

          -  Female participants who are pregnant or breastfeeding.

          -  Body Mass Index (BMI) &gt; 36 kg/m2.

          -  Co-infected with hepatitis B virus or human immunodeficiency virus (HIV).

          -  History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC.

          -  History or signs of decompensated liver disease: ascites, variceal bleeding, hepatic
             encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal
             hypertension or hepatic insufficiency.

          -  Has one or more known primary or secondary causes of liver disease, other than
             hepatitis C

          -  History of, or active, acute or chronic, liver or biliary injury due to drugs, toxins,
             non-HCV viral hepatitis, gallstones or other etiologies

          -  Donated blood or had significant blood loss 30 days prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2013</study_first_posted>
  <last_update_submitted>April 22, 2015</last_update_submitted>
  <last_update_submitted_qc>April 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>chronic hepatitis C</keyword>
  <keyword>antiviral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

